Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000663250 | SCV000786475 | likely pathogenic | Colorectal cancer, susceptibility to, 12 | 2018-05-08 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003656131 | SCV001385287 | pathogenic | not provided | 2022-05-27 | criteria provided, single submitter | clinical testing | This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with POLE-related conditions. ClinVar contains an entry for this variant (Variation ID: 548907). This sequence change creates a premature translational stop signal (p.Glu978*) in the POLE gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in POLE are known to be pathogenic (PMID: 23230001, 25948378, 30503519). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. For these reasons, this variant has been classified as Pathogenic. |
Ambry Genetics | RCV000758173 | SCV002750188 | uncertain significance | Hereditary cancer-predisposing syndrome | 2019-05-15 | criteria provided, single submitter | clinical testing | The p.E978* variant (also known as c.2932G>T), located in coding exon 25 of the POLE gene, results from a G to T substitution at nucleotide position 2932. This changes the amino acid from a glutamic acid to a stop codon within coding exon 25. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. However, loss of function via haploinsufficiency in POLE has not been clearly established as a mechanism of disease. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
True Health Diagnostics | RCV000758173 | SCV000886709 | pathogenic | Hereditary cancer-predisposing syndrome | 2018-08-09 | no assertion criteria provided | clinical testing |